Innoviva (Innoviva) Interest Expense : $-20.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Innoviva Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Innoviva's interest expense for the three months ended in Mar. 2024 was $ -5.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-20.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Innoviva's Operating Income for the three months ended in Mar. 2024 was $ 25.8 Mil. Innoviva's Interest Expense for the three months ended in Mar. 2024 was $ -5.9 Mil. Innoviva's Interest Coverage for the quarter that ended in Mar. 2024 was 4.41. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innoviva Interest Expense Historical Data

The historical data trend for Innoviva's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Interest Expense Chart

Innoviva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-18.66

-18.33

-19.07

-15.79

-19.16

Innoviva Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-4.43	-4.38	-4.40	-5.95	-5.85

Innoviva Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.6 Mil.

Innoviva (NAS:INVA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innoviva's Interest Expense for the three months ended in Mar. 2024 was $-5.9 Mil. Its Operating Income for the three months ended in Mar. 2024 was $25.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $448.1 Mil.

Innoviva's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	25.805	/	-5.851
	=	4.41

The higher the ratio, the stronger the company's financial strength is.

Innoviva (Innoviva) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

HVE:Germany HVE:Germany

Address

1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010

Website

https://www.inva.com

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Executives

Marianne Zhen	officer: Chief Accounting Officer	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso	officer: Chief Financial Officer	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel	officer: Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx	director	3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld	officer: Chief Executive Officer	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava	director	C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards	officer: CEO of La Jolla Pharmaceutical	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511